All results with different innate immune pathways suggest that MyD88 is essential for BCG-tumor treatment depending on a synergistic effect involving several MyD88-dependent TLRs working simultaneously and/or a TLR-independent effect. This evidence concerns the gene MYD88 and neoplasm.